LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN

13841 reported adverse events

Drug classes: Radioligand Therapeutic Agent [EPC]

These side effects are most commonly reported by patients taking LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN:

# Side effect Count
0 GENERAL PHYSICAL HEALTH DETERIORATION 6684
1 ILL-DEFINED DISORDER 3641
2 DEATH 1321
3 DISEASE PROGRESSION 360
4 MALIGNANT NEOPLASM PROGRESSION 343
5 PROSTATIC SPECIFIC ANTIGEN INCREASED 287
6 LABORATORY TEST ABNORMAL 266
7 FATIGUE 238
8 ANAEMIA 204
9 PLATELET COUNT DECREASED 168
See all common reactions for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN